Spravato is a nasal spray FDA approved for two kinds of depression in adults. Ketamine is an approved anesthetic that doctors can also prescribe for depression [1] [4] [13]. Esketamine, the drug in Spravato, is one of the two mirror-image forms that make up ketamine, but the two sit under very different rules. This page explains which is which, where you can take each one, what the research shows, and the questions worth asking before you start. It was last checked on November 17, 2026.
The short version
- Spravato is FDA approved for two kinds of depression in adults. It is a nasal spray of esketamine, one form of the ketamine molecule, approved for treatment-resistant depression in adults, alone or with an oral antidepressant, and, with an oral antidepressant, for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior [1].
- You take Spravato at a certified clinic, never at home, and a healthcare provider monitors you for at least two hours afterward [1].
- Ketamine is FDA approved as an anesthetic, not for depression. It can still be prescribed for psychiatric conditions, outside the Spravato safety program [4] [13].
- Both are Schedule III controlled substances under federal law, so they can be prescribed and are tightly regulated [1] [5]. States keep their own schedules too. Montana, for example, also lists ketamine in Schedule III [14].
- The VA has studied ketamine for PTSD and has guidance on it for some nerve pain. The U.S. Department of Veterans Affairs (VA) sponsored a trial of ketamine added to prolonged exposure therapy for veterans with post-traumatic stress disorder (PTSD) [15]. VA national protocol guidance covers ketamine infusions, as part of a broader pain care plan, for some veterans in VHA pain care with treatment-resistant neuropathic pain, a type of chronic pain [16]. The 2023 VA/DoD PTSD guideline suggests against ketamine as a treatment for PTSD [17].
- The research is mixed. Trials show benefit in treatment-resistant depression, and reviews differ on how large it is [7] [8] [9] [10].
Spravato (esketamine)
What it is approved for. The FDA first approved Spravato in March 2019 for adults with depression who had tried other antidepressants without benefit, used with an oral antidepressant [2]. Use on its own for treatment-resistant depression was added in January 2025 [3]. The label says it has not been shown to prevent suicide or reduce suicidal thoughts or behavior [1].
Where and how you take it. Spravato is available only through a federal safety program called a REMS (Risk Evaluation and Mitigation Strategy). It is dispensed and given only in certified healthcare settings, outpatients must be enrolled in the program, and you take the spray yourself while a healthcare provider watches. Because of the risks of sedation, dissociation and slowed breathing, the provider monitors you for at least two hours after each dose. Blood pressure is checked before the dose and again after it [1].
Getting home. No driving until the next day, after a restful sleep, so plan a ride home after each treatment [1].
The warnings. Spravato carries a boxed warning for sedation, dissociation (feeling detached from yourself or your surroundings), slowed breathing, abuse and misuse, and suicidal thoughts and behaviors. It is not given to people with certain blood vessel conditions, such as an aneurysm, to people with a history of bleeding in the brain, or to people allergic to esketamine or ketamine [1].
Ketamine for depression (off-label)
What it is approved for. Ketamine is FDA approved as an injection for general anesthesia. The FDA says ketamine "is not FDA approved for the treatment of any psychiatric disorder," and that it "has not established safe or effective dosing" for any psychiatric use [4]. Doctors may still prescribe it for psychiatric conditions, and that use is not part of the Spravato safety program [13].
At-home and telehealth ketamine. In 2023 the FDA warned about compounded ketamine, made by compounding pharmacies, including forms taken by mouth. It said that without a provider on site to watch for sedation and dissociation, patients may be at risk, and it described a patient whose breathing slowed dangerously after taking compounded oral ketamine for PTSD outside a health care setting [4]. The CDC lists the risks of unmonitored use as too much sedation, dissociation, changes in vital signs, non-fatal overdoses, bladder damage and substance use disorder [13].
Prescribing by video. Temporary federal rules from the DEA and the Department of Health and Human Services let authorized practitioners prescribe certain controlled medicines, ketamine among them, by telehealth without first seeing the patient in person, through December 31, 2026, under the rules' conditions [5] [6]. Those rules may change after that date. They do not settle whether a particular at-home service follows state law.
What the research shows
Esketamine compared with another medicine. In a 2023 trial of 676 adults with treatment-resistant depression, all still taking an SSRI or SNRI, 27.1% of those given esketamine were in remission at week 8, compared with 17.6% of those given quetiapine. The maker of Spravato paid for the trial, and patients knew which treatment they had, though the people rating their depression did not [7].
Ketamine compared with ECT. In a 2023 open-label trial in people with treatment-resistant depression without psychosis, intravenous ketamine proved no less effective than electroconvulsive therapy (ECT) on its main measure after three weeks. ECT was linked to muscle and joint side effects, and ketamine to dissociation [8].
What reviews and guidelines conclude. A 2021 Cochrane review found ketamine and esketamine may work better than placebo at 24 hours, but said it is not entirely clear how that translates into everyday care [9]. A 2025 review found esketamine's benefit as an add-on in treatment-resistant depression to be modest, and found no significant effect on suicidality at any time point [10]. The 2022 Veterans Affairs and Department of Defense guideline suggests ketamine or esketamine as an add-on option for people with major depression who have not responded to several medicine trials, and rates that suggestion as weak [12].
Where it is used and studied. Several nationally recognized healthcare institutions, including Yale University, Johns Hopkins Medicine, Mount Sinai Health System, and Cleveland Clinic, have participated in the clinical use and research of ketamine-based therapies, particularly for treatment-resistant depression [18] [19] [20] [21]. Additionally, the Department of Veterans Affairs has developed national clinical guidance for ketamine infusions in certain treatment-resistant neuropathic pain conditions [16]. These institutions demonstrate the growing medical interest in ketamine as a potential therapeutic option for complex conditions that may not respond adequately to conventional treatments.
Risks to know about
- During and right after a session: sedation, dissociation, slowed breathing and a rise in blood pressure, which is why Spravato requires monitoring and blood pressure checks [1].
- Bladder problems: painful bladder inflammation has been reported with long-term off-label use or misuse of ketamine. The Spravato label reports more lower urinary tract symptoms than with placebo, but no esketamine-related interstitial cystitis in studies of up to a year [1]. A 2022 review found no reports of severe bladder disease at depression treatment doses [11].
- Memory: long-term memory and thinking problems have been reported with repeated ketamine misuse. In Spravato trials lasting one and three years, thinking skills stayed stable [1].
Questions to ask a clinic
Each of these comes straight from the label, the FDA or the CDC:
- Is this Spravato under the REMS program, or off-label ketamine, and is it compounded [1] [4] [13]?
- Is the clinic certified for Spravato, and am I enrolled [1]?
- Who watches me, for how long, and who decides when I can leave [1]?
- When will you check my blood pressure [1]?
- How do I get home [1]?
- What do you need to know about my health history and other medicines [1]?
- How will we decide whether it is working [1]?
- For off-label ketamine taken at home: who is monitoring me [4]?
Common questions
Is Spravato the same as ketamine?
No. Spravato is esketamine, one form of the ketamine molecule, made as a nasal spray and FDA approved for two kinds of depression in adults [1]. Ketamine itself is approved as an anesthetic, and its use for depression is outside that approval [4] [13].
Can I take Spravato at home?
No. Spravato is given only in certified healthcare settings, with at least two hours of monitoring afterward [1].
Is at-home ketamine legal?
Ketamine may be prescribed for psychiatric conditions [13], and temporary federal rules allow authorized practitioners to prescribe it through a qualifying telehealth visit through December 31, 2026 [6]. Those federal rules do not settle whether a particular at-home service follows state law. The FDA has warned that taking compounded ketamine without a provider on site may put patients at risk [4].
Can I drive after a session?
Not after Spravato. The label says not to drive until the next day, after a restful sleep [1]. Ask an off-label ketamine clinic about its own rules.
Is ketamine a psychedelic?
Ketamine is an anesthetic, and dissociation is one of its known effects [1] [4]. For where psilocybin approval stands, see Psilocybin and the FDA.
Sources (21)
- SPRAVATO (esketamine) nasal spray, prescribing information. DailyMed, National Library of Medicine, 2026.
- FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic (archived). U.S. Food and Drug Administration, 2019.
- SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. Johnson & Johnson, 2025.
- FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders (archived). U.S. Food and Drug Administration, 2023.
- 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations, 2026.
- Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register (DEA and HHS), 2025.
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine, 2023.
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 2023.
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database of Systematic Reviews, 2021.
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry, 2025.
- Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety, 2022.
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder, version 4.0. U.S. Department of Veterans Affairs and Department of Defense, 2022.
- Responding to Disruption Events Involving Esketamine and Ketamine. Centers for Disease Control and Prevention, 2026.
- Montana Code Annotated 50-32-226, Specific dangerous drugs included in Schedule III. Montana Legislature, 2025.
- Repeated Ketamine Treatment to Accelerate Efficacy of Prolonged Exposure in PTSD (NCT04560660). ClinicalTrials.gov, National Library of Medicine (sponsor VA Office of Research and Development), 2026.
- Ketamine Infusion for the Treatment of Intractable Neuropathic Pain for Veterans Being Cared for by VHA Pain Specialists or Pain Management Teams, National Protocol Guidance (December 2024 update). VA Pharmacy Benefits Management Services, 2024.
- VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder, version 4.0, Quick Reference Guide. U.S. Department of Veterans Affairs and Department of Defense, 2023.
- Yale-Led Study Will Compare Effectiveness of IV Ketamine and Esketamine Nasal Spray. Yale School of Medicine, Department of Psychiatry, 2025.
- Johns Hopkins Clinician-Scientists Participate in National Study on Ketamine vs. ECT for Treatment-Resistant Depression. Johns Hopkins Medicine, 2023.
- Treatment-Resistant Depression Program. Mount Sinai Health System, 2026.
- Treatment-Resistant Mental Healthcare. Cleveland Clinic, 2026.